Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Head and Neck Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1484002

The Relationship Between Lateral Cervical Lymph Node Positivity Rate and Recurrence After Comprehensive Treatment in Differentiated Thyroid Carcinoma: A Single-Center Retrospective Cohort Study from China

Provisionally accepted
Ting Ye Ting Ye 1Shihan Shao Shihan Shao 2*Shulin Yao Shulin Yao 1*Ruimin Wang Ruimin Wang 1*
  • 1 Department of Nuclear Medicine, the First Medical Center, Chinese PLA General Hospital, beijing, China
  • 2 Department of Hepatobiliary Surgery, The Sixth Medical Center, Chinese PLA General Hospital, Beijing, China

The final, formatted version of the article will be published soon.

    The lateral cervical lymph node positivity rate has been hypothesized to correlate with the recurrence risk in differentiated thyroid carcinoma (DTC) patients. However, the extent of this association within the Chinese population remains understudied. This study seeks to elucidate the potential causal link between the lymph node positivity rate and DTC recurrence.We conducted a retrospective cohort study, examining clinical records of 4,731 DTC patients who received surgical treatment at the First Medical Center of the General Hospital of the Chinese People's Liberation Army from January 2015 to May 2020. The study variables encompassed demographic and clinical characteristics, including sex, age, tumor size, location, laterality, capsular invasion, lymph node metastasis counts, lymph node positivity rates, histological subtypes, Hashimoto's thyroiditis co-occurrence, and the timing of iodine-131 therapy post-surgery. After applying strict inclusion criteria, 1,074 patients were selected for analysis.Recurrence was defined as structural incomplete response (SIR), confirmed by imaging or histological means.The lymph node positivity rate was calculated as the proportion of positive lymph nodes to the total lymph node count.Results: Multivariate analysis revealed a nonlinear association between the lateral cervical lymph node positivity rate and post-treatment recurrence, with a significant threshold at 0.5. The recurrence risk was substantially elevated with a positivity rate below this threshold (HR: 27.48, 95% CI: 7.21-104.70, P<0.0001), while no significant association was observed above it (HR: 0.17, 95% CI: 0.02-1.57, P=0.119). Subgroup analysis within the high-risk cohort did not yield a significant association between the positivity rate and recurrence risk (HR=0.43, 95% CI: 0.10-1.79, P=0.246).In conclusion, this study identifies a nonlinear relationship between the lateral cervical lymph node positivity rate and the risk of DTC recurrence post-treatment. A positivity rate of less than 0.5 is positively associated with recurrence, while this association diminishes in significance among high-risk patients.This differs from the results previously reported. Further studies are needed to determine the potential mechanisms of the associations observed in observational studies.

    Keywords: Differentiated thyroid carcinoma, Lateral Cervical Lymph Node Positivity Rate, Post-Treatment Recurrence, Association, structural incomplete response

    Received: 09 Dec 2024; Accepted: 28 Jan 2025.

    Copyright: © 2025 Ye, Shao, Yao and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Shihan Shao, Department of Hepatobiliary Surgery, The Sixth Medical Center, Chinese PLA General Hospital, Beijing, China
    Shulin Yao, Department of Nuclear Medicine, the First Medical Center, Chinese PLA General Hospital, beijing, China
    Ruimin Wang, Department of Nuclear Medicine, the First Medical Center, Chinese PLA General Hospital, beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.